Who owns Tempalgin?
Tempalgin is owned by Sopharma (Bulgaria, BSE Sofia: SFA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Key facts
- Current owner
- Sopharma AD reported
- Owned since
- Not recorded
- Previous owner
- None recorded
- Owner HQ
- 🇧🇬 Bulgaria, Sofia
- Origin
- 🇧🇬 Bulgaria
- Category
- Consumer health › Over-the-counter medicine › Pain relief
- Parent ticker
- BSE Sofia: SFA WSE: SPH
- Last verified
- · 1 sources
About Tempalgin
Tempalgin is Sopharma's combination painkiller, a film-coated tablet of 500 mg metamizole with 20 mg triacetonamine 4-toluenesulfonate, and the company lists it among the six brands it calls its leading strategic products in consumer healthcare. Its Albanian authorisation was renewed in the first half of 2026 and a Belarusian registration was submitted in the same period, while a reformulated tablet is among the thirty-three products in pharmaceutical development.
Ownership timeline of Tempalgin
Where Tempalgin sits in Sopharma
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Sopharma ownership tree →
Other brands owned by Sopharma in consumer health
Latest news about Tempalgin
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who is the parent company of Tempalgin?
The parent company of Tempalgin is Sopharma, a publicly listed company headquartered in Bulgaria.
Is Tempalgin Bulgarian?
Yes. Tempalgin originated in Bulgaria and its owner, Sopharma, is also headquartered in Bulgaria.
Is Tempalgin still owned by Sopharma?
Yes. As of 20 September 2026, Tempalgin is still owned by Sopharma. The ownership record was last checked against primary sources on that date.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Sopharma Group consolidated management report for the first half of 2026 — Sopharma AD, Stock exchange filing, published 30 June 2026; retrieved 20 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.